Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7725940 | 0.84 | HDAC11 (0.43) | FBP1NPBWR1METDGAT1KCNH2 | |
| SCHEMBL6826888 | 0.83 | FBP1 (0.38) | FBP1 | |
| SCHEMBL6826904 | 0.77 | DGAT1 (0.40) | FBP1NPBWR1DGAT1KCNH2 | |
| SCHEMBL6826910 | 0.75 | NPBWR1 (0.51) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL6831934 | 0.70 | FBP1 (0.40) | FBP1 | |
| SCHEMBL6826883 | 0.70 | EGLN1 (0.41) | FBP1 | |
| SCHEMBL6829765 | 0.70 | MMP2 (0.56) | FBP1 | |
| SCHEMBL6830822 | 0.70 | FBP1 (0.41) | FBP1 | |
| SCHEMBL6831919 | 0.70 | FBP1 (0.41) | FBP1 | |
| SCHEMBL6830165 | 0.70 | FBP1 (0.41) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1402895-A1 | Benzimidazole inhibitors of fructose 1,6-biphosphatase | Metabasis Therapeutics, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0970095-B1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6399782-B1 | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6110903-A | INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE AT THE AMP SITE; ADMINISTERING TO TREAT DIABETES AND INHIBIT GLUCONEOGENESIS; 5-FLUORO-7-BROMO-1-ISOBUTYL-2-(2-PHOSPHONO-5-FURANYL) BENZIMIDAZOLE, FOR EXAMPLE | SANKYO COMPANY LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0970095-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039343-A9 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039343-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |